COPENHAGEN, Denmark, September 19, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the European Commission has adopted the Committee for Medicinal Products for Human Use (CHMP) recommendation for the approval of a type II variation for IMVANEX® (MVA-BN) smallpox and mpox vaccine, extending the current marketing authorization to include adolescents 12 to 17 years of age.

Enhancing Protection for Adolescents

This recent development in the approval of IMVANEX® for adolescents marks a significant step forward in ensuring the health and safety of young individuals within the European Union. Smallpox and monkeypox are serious infectious diseases that can have detrimental effects on individuals of all ages, and extending the authorization of this vaccine to include adolescents will help to enhance overall protection against these viruses.

The Importance of Vaccination

Vaccination plays a crucial role in preventing the spread of infectious diseases and safeguarding public health. By expanding the approval of IMVANEX® to adolescents, Bavarian Nordic A/S is contributing to the overall effort of vaccination campaigns aimed at eradicating smallpox and controlling outbreaks of monkeypox. This decision highlights the commitment to ensuring that individuals of all age groups have access to effective vaccines.

Implications for Public Health

The approval of IMVANEX® for adolescents not only benefits the younger population but also has broader implications for public health. Vaccinating adolescents against smallpox and monkeypox can help create a more resilient and protected community, reducing the overall burden of these diseases and preventing potential outbreaks. This decision underscores the importance of continuous research and development in the field of vaccination.

The Global Impact

Expanding the marketing authorization of IMVANEX® to include adolescents in the European Union sets a precedent for other regions to follow suit. The global impact of this decision extends beyond the borders of Europe, as it reinforces the importance of ensuring that vaccines are accessible to individuals of all ages. By prioritizing the health and well-being of adolescents, Bavarian Nordic A/S is contributing to a safer and more secure world.

Conclusion

The approval of a type II variation for IMVANEX® for adolescents represents a significant milestone in the field of vaccination. This decision not only enhances protection for young individuals but also has far-reaching implications for public health and the global community. By extending the marketing authorization of this vaccine, Bavarian Nordic A/S is advancing the fight against infectious diseases and promoting a healthier future for all.